(Q36548362)

English

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents

scientific article published on 27 July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

1 reference

Europe PubMed Central

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

stem cell transplantation

1 reference

based on heuristic

inferred from title

author name string

Barrett AJ

1

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Savani BN

2

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

publication date

27 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

1661-1672

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404334

0 references

Bone-marrow transplantation (second of two parts).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Mixed allogeneic chimerism as an approach to transplantation tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Mixed chimerism: preclinical studies and clinical applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

New strategies for bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specif

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Haploidentical stem cell transplantation: the always present but overlooked donor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Graft-versus-host disease in mini-transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripher

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell se

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Transplant strategies for patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Loss of response to imatinib: mechanisms and management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

21 January 2018

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

New Developments in the Therapy of Acute Myelocytic Leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome after allogeneic bone marrow transplant for leukemia in older adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404334

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404334

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Dimensions Publication ID

0 references

release_fe2odq4yzfboxpk4cuj2ws2eg4

1 reference

https://api.fatcat.wiki/v0/release/fe2odq4yzfboxpk4cuj2ws2eg4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36548362&oldid=1836368214"